Artelo Biosciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

INTANGIBLE ASSET

INTANGIBLE ASSET	3 Months Ended
Mar. 31, 2022
INTANGIBLE ASSET
Note 4 - Intangible Asset	NOTE 4 – INTANGIBLE ASSET The Company has capitalized the costs associated with acquiring the exclusive worldwide license to develop and commercialize products comprising or containing the proprietary therapeutic compound ART27.13, formerly known as NEO1940 as an intangible asset at a value of $2,039 as of March 31, 2022, and December 31, 2021. The amount capitalized consisted of a $1,500 payment and the fair value of 61,297 shares of common stock of $539. During the three months ended March 31, 2022, no additional costs met the criteria for capitalization as an intangible asset.

INTANGIBLE ASSET

3 Months Ended

Mar. 31, 2022

NOTE 4 – INTANGIBLE ASSET

The Company has capitalized the costs associated with acquiring the exclusive worldwide license to develop and commercialize products comprising or containing the proprietary therapeutic compound ART27.13, formerly known as NEO1940 as an intangible asset at a value of $2,039 as of March 31, 2022, and December 31, 2021.

The amount capitalized consisted of a $1,500 payment and the fair value of 61,297 shares of common stock of $539. During the three months ended March 31, 2022, no additional costs met the criteria for capitalization as an intangible asset.